Regeneron Pharmaceuticals (NASDAQ:REGN) Director Kathryn Guarini Sells 400 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $900.00, for a total transaction of $360,000.00. Following the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $542,700. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathryn Guarini also recently made the following trade(s):

• On Wednesday, September 2nd, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $850.00, for a total value of $340,000.00.
• On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $800.00, for a total value of $320,000.00.

Regeneron Pharmaceuticals Trading Up 1.3%

Shares of NASDAQ:REGN traded up $12.10 during trading on Tuesday, reaching $973.36. The stock had a trading volume of 1,198,078 shares, compared to its average volume of 828,291. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $975.49. The business has a fifty day moving average price of $795.85 and a 200-day moving average price of $739.07. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $100.21 billion, a P/E ratio of 21.49, a PEG ratio of 1.37 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $11.83 EPS. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $5,682,636,000. State Street Corp lifted its stake in shares of Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after purchasing an additional 170,210 shares during the last quarter. Bank of America Corp DE boosted its holdings in Regeneron Pharmaceuticals by 8.5% in the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock worth $805,023,000 after purchasing an additional 101,469 shares in the last quarter. Amundi increased its position in Regeneron Pharmaceuticals by 0.4% during the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after buying an additional 3,742 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $473,872,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported Q3 revenue of $5.12 billion, up 36.3% year over year and above expectations of $4.58 billion. EPS of $20.07 also topped the $16.51 consensus. The beat and strength in core commercial products underpin the bullish reaction. Q3 results and pipeline progress
• Positive Sentiment: Multiple firms lifted their targets following the results. JPMorgan raised its target to $1,050 and maintained an Overweight rating; Guggenheim raised its target to $1,100 and kept a Buy rating. Some analyst forecasts reportedly reached $1,175. Analysts raise forecasts
• Neutral Sentiment: Analyst views are not uniformly bullish. Although several firms raised targets, RBC, Morgan Stanley, Bernstein and others retained market-perform, sector-perform or equal-weight ratings, with some targets below the stock’s recent level—suggesting limited upside in their estimates. RBC assessment of commercial performance
• Neutral Sentiment: CNBC traders named REGN among their “Final Trades” after the strong Q3 report, but the mention does not provide a new company-specific catalyst. CNBC Final Trades

Analyst Upgrades and Downgrades

A number of brokerages have commented on REGN. Jefferies Financial Group lifted their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a research note on Friday. Royal Bank Of Canada upped their target price on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a research report on Monday. Cantor Fitzgerald lifted their price target on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Bank of America boosted their price objective on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $898.97.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.